De Rosch Mark 4

What Happened

• Mark De Rosch, EVP, Regulatory Affairs & Global Access and Program Management at CervoMed (CRVO), was granted 30,000 derivative shares (award code A) on 2026-02-11. The award is reported at $0.00 per share in the Form 4, meaning no cash purchase; value will depend on CervoMed’s stock price when/if shares vest or are issued.

Key Details

• Transaction date: 2026-02-11; Form 4 filed 2026-02-13 (filed within the normal reporting window).
• Transaction type/code: Grant / Award (A); 30,000 shares acquired at $0.00 (derivative securities).
• Vesting: The shares underlying the award vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month, commencing February 28, 2026 (footnote F1).
• Shares owned after transaction: Not specified in the excerpt of the filing provided.
• No indication of a sale, exercise, or tax withholding reported in this transaction.

Context

• This appears to be a time-based equity award (commonly RSUs or similar). Such awards are subject to vesting and restrictions and do not represent immediately tradable shares until vested/issued.
• Because the grant price is $0.00, there was no cash outlay by the insider; the economic value will depend on future stock price and whether/how shares are settled. The filing was timely (reported within expected SEC deadlines).